FR2937550B1 - Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion - Google Patents

Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion

Info

Publication number
FR2937550B1
FR2937550B1 FR0806004A FR0806004A FR2937550B1 FR 2937550 B1 FR2937550 B1 FR 2937550B1 FR 0806004 A FR0806004 A FR 0806004A FR 0806004 A FR0806004 A FR 0806004A FR 2937550 B1 FR2937550 B1 FR 2937550B1
Authority
FR
France
Prior art keywords
citrulline
ischemia
prevention
treatment
reperfusion syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0806004A
Other languages
English (en)
Other versions
FR2937550A1 (fr
Inventor
Bandt Jean Pascal Jean Pierre Michel De
Christophe Moinard
Luc Cynober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris 5 Rene Descartes
Original Assignee
Universite Paris 5 Rene Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris 5 Rene Descartes filed Critical Universite Paris 5 Rene Descartes
Priority to FR0806004A priority Critical patent/FR2937550B1/fr
Publication of FR2937550A1 publication Critical patent/FR2937550A1/fr
Application granted granted Critical
Publication of FR2937550B1 publication Critical patent/FR2937550B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0806004A 2008-10-29 2008-10-29 Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion Expired - Fee Related FR2937550B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0806004A FR2937550B1 (fr) 2008-10-29 2008-10-29 Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806004A FR2937550B1 (fr) 2008-10-29 2008-10-29 Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion

Publications (2)

Publication Number Publication Date
FR2937550A1 FR2937550A1 (fr) 2010-04-30
FR2937550B1 true FR2937550B1 (fr) 2010-12-10

Family

ID=40568554

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0806004A Expired - Fee Related FR2937550B1 (fr) 2008-10-29 2008-10-29 Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion

Country Status (1)

Country Link
FR (1) FR2937550B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
RU2611357C1 (ru) * 2015-09-10 2017-02-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" министерства здравоохранения Российской Федерации Способ профилактики реперфузионного синдрома при реконструктивных операциях на прецеребральных сосудах

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874471A (en) * 1997-02-27 1999-02-23 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
JP3843298B2 (ja) * 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤

Also Published As

Publication number Publication date
FR2937550A1 (fr) 2010-04-30

Similar Documents

Publication Publication Date Title
FR23C1003I2 (fr) Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
FR20C1066I2 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
EP2007385A4 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
SMT201600182B (it) Ligandi sigma per l'uso nella prevenzione e/o nel trattamento del dolore post-operatorio
HK1134679A1 (zh) 用於治療感染的組合物和方法
PL2546253T3 (pl) Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
EP2079526A4 (fr) Compositions et leurs utilisations dans le traitement de lésions
HK1139861A1 (en) Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
FR2899476B1 (fr) Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
EP2056857A4 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
FR2897533B1 (fr) Agent oxydant pour le traitement des cheveux
FR2917947B1 (fr) Composition phytosanitaire pour le traitement preventif et curatif du mildiou
FR2937550B1 (fr) Utilisation de la citrulline pour le traitement et la prevention du syndrome d'ischemie-reperfusion
FR2901703B1 (fr) Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques
FR2962041B1 (fr) Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
FR2902321B1 (fr) Utilisation de curcumin pour le traitement de la canitie
FR2936712B1 (fr) Composition pour la prevention et/ou le traitement de l'arthrose
BR112012025829A2 (pt) ''composição de tratamento, composição líquido e utilização''
FR2933301B1 (fr) Extrait de cannelle pour la prevention et/ou le traitement des infections urinaires

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20180629